PET Scans Targeting LRRC15 to Find and Stage Several Cancers
Tests a new LRRC15-targeted PET scan in adults with suspected or confirmed cancers.
Key facts
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Where
- Wuhan, ChinaSee the site
- Trial code
- Registry title
- Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
- Status
- Recruiting
- People taking part
- 26 people, planned
- Started
- 1 Apr 2026
- Expected to end
- 31 Mar 2027
- Type of study
- Observational
- Treatments tested
- Specific PET imaging agents targeting LRRC15
- Record updated
- 27 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 or older, either healthy volunteers or patients with suspected or confirmed cancer, who will have a PET scan with a tracer aimed at LRRC15.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Suspected or confirmed cancer, such as pancreatic, breast, lung, head and neck, colorectal cancer, sarcoma, glioblastoma or melanoma, in good general condition. Healthy volunteers can also join.
Main reasons for not taking part
- Cannot lie flat or complete a PET/MR or PET/CT scan, for example because of claustrophobia
- Acute systemic illness or electrolyte imbalance
- Known allergy to the LRRC15 tracer or its ingredients
- Fasting blood glucose above 11.0 mmol/L (198 mg/dL) before [¹⁸F]FDG injection
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Each subject must meet all of the following inclusion criteria to be eligible for study enrollment:
- The subject or their legally authorized representative (LAR) is capable of providing a signed and dated informed consent form (ICF)
- Willing and able to comply with all study procedures and cooperate throughout the entire duration of the study
- Adult patients or healthy volunteers, aged 18 years or older, male or female
- Patients with clinically suspected or confirmed malignancies (supported by evidence such as relevant serum tumor markers, imaging modalities including ultrasound, CT, and MRI, or histopathological examinations) who are in good general condition
- Women of childbearing potential (WOCBP) must have used effective contraception for at least one month prior to screening and agree to continue contraceptive use throughout the study period and for a specified duration following study completion
- Must meet any other protocol-specified inclusion criteria
Who cannot take part
- Presence of other comorbidities, such as acute systemic illnesses and electrolyte imbalances
- Presence of any other conditions or factors that, in the opinion of the investigator, would make the subject unsuitable for participation in this trial
- Known allergy or hypersensitivity to the LRRC15 radiotracer or its synthetic excipients; fasting blood glucose level exceeding 11.0 mmol/L prior to [¹⁸F]FDG injection
- Any subject meeting any of the following baseline criteria will be excluded from the study:
- Inability to tolerate or complete PET/MR or PET/CT examinations (including, but not limited to, the inability to lie supine, claustrophobia, radiophobia, etc.)
- Patients deemed by the investigator to have poor expected compliance
- Pregnant or lactating (nursing) women
Where in China
- Wuhan Union Hospital, ChinaWuhan, ChinaContact: Xiaoli Lan, PhDTaking people
About the trial
What the trial wants to find out
This project utilizes LRRC15-specific targeted PET radiotracers to perform PET/MR or PET/CT imaging on healthy volunteers and patients with clinically suspected or confirmed malignancies characterized by high LRRC15 expression-including pancreatic cancer, breast cancer, lung cancer, sarcoma, head and neck tumors, glioblastoma, colorectal cancer, and melanoma. The study aims to achieve the following objectives:
Read full original descriptionShow less
For patients with malignant tumors: To diagnose and stage the disease. By comparing the imaging results against the gold standard of histopathological diagnosis, the study aims to evaluate diagnostic efficacy, ascertain the presence or absence of lesions, and characterize their anatomical location and nature. Furthermore, through comparison with [¹⁸F]FDG PET or [⁶⁸Ga]Ga-FAPI PET, the study seeks to achieve accurate disease staging, assess tumor burden, and facilitate therapeutic decision-making.
For healthy volunteers: To conduct pharmacokinetic analyses to determine the in vivo biodistribution and metabolic patterns of the radiotracer, as well as to evaluate its safety profile.
Treatments tested
- Specific PET imaging agents targeting LRRC15
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
- Plain-language title
- PET Scans Targeting LRRC15 to Find and Stage Several CancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 April 2026